What is Biogen's felzartamab (amr) — intangible assets:?

Biogen (BIIB) reported felzartamab (amr) — intangible assets: of $450.00M in Q2 2024.

What does felzartamab (amr) — intangible assets: mean?

The total book value of intellectual property and development assets associated with the Felzartamab (AMR) drug program.

Discontinued — last reported Q2 '24

Products & Services · Intangible assets:

Felzartamab (AMR) — Intangible assets:

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ2 2024

Last reportedQ2 2024

Rolls up toIntangibles (Net)

How to read this metric

An increase typically reflects continued investment or acquisition of rights related to the asset, while a decrease may indicate amortization, impairment charges, or a strategic shift in development priorities.

Detailed definition

This metric represents the capitalized value of intangible assets specifically attributed to the Felzartamab (AMR) produ...

Peer comparison

Comparable to capitalized R&D or acquired intangible assets reported by other biopharmaceutical companies for specific high-value pipeline candidates.

Metric ID: biib_segment_felzartamab_amr_intangible_assets

Historical Data

1 periods

	Q2 '24
Value	$450.00M

Similar Metrics at Other Companies

ViatrisVTRS View metric

Flex Ltd.FLEX View metric

ViatrisVTRS View metric

Becton, Dickinson and CompanyBDX View metric

ViatrisVTRS View metric

Vertex PharmaceuticalsVRTX View metric

Frequently Asked Questions

What is Biogen's felzartamab (amr) — intangible assets:?: Biogen (BIIB) reported felzartamab (amr) — intangible assets: of $450.00M in Q2 2024.
What does felzartamab (amr) — intangible assets: mean?: The total book value of intellectual property and development assets associated with the Felzartamab (AMR) drug program.